Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials

Eli Lilly and Company announced today it will discontinue development of tabalumab¬≠ — being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) — due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns

Read more here:
Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share